Carisma Therapeutics to report latest data from Phase 1 trial of CT-0508

Carisma Therapeutics will present findings at the 8th Annual CAR-TCR Summit from its Phase 1 clinical trial of the company’s lead product candidate, CT-0508, a human epidermal growth factor receptor 2 targeted chimeric antigen receptor macrophage for the treatment of advanced/metastatic HER2 overexpressing cancers. The presentation includes data from group 1 and group 2. Patients in both groups received the same total dose either via a fractionated, multi-day infusion regimen or via a single-day bolus infusion. The data are drawn from the ongoing clinical trial led by Kim A. Reiss, MD, principal investigator of the Phase 1 clinical trial and an associate professor of Hematology-Oncology in the Perelman School of Medicine at the University of Pennsylvania. In the presentation, Michael Klichinsky, PharmD, PhD, Co-Founder and Chief Scientific Officer at Carisma, will present data demonstrating that, in both groups, CT-0508 was successfully manufactured for patients and that the administration of CT-0508 was well-tolerated after infusion with no dose-limiting toxicities reported to date.